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Objectives. This study was undertaken to assess myocardial 
adrenergic activity using iodine-123 metaiodobenzylgnanidine 
(MIBG) imaging in patients with heart failure. 
Background. In patients with congestive heart failure, adren. 
ergic nerve activity is accelerated. However, whether myocardial 
adrenergic nerve activity reflects the severity of heart failure and 
its relation to the underlying cause have not yet been elucidated. 
Methods. Planar MIBG images were obtained from 96 patients 
with heart failure and compared with images from 9 age-matched 
healthy subjects. Groups 1 and 2 included 65 patients with heart 
failure related to impaired myocardial function and whose left 
veutricular ejection fraction was <40% (group 1 = 40 patients 
with dilated cardiomyopathy; group 2 = 25 patients with iscbemic 
cardiomyopathy). Group 3 included 31 patients with heart failure 
related to a mechanical abnormality and whose left ventricular 
ejection fraction was >40% (mitral regurgitation in 16, aortic 
regurgitation in 9, aortic and mitral regurgitation in 4, ruptured 
aneurysm of Valsalva in 2). Myocardial uptake of MIBG was 
calculated as the heart/mediastinal activity ratio. Storage and 
release of MIBG were calculated as percent myocardial MIBG 
washout from 15 min to 4 h after isotope injection. 
Results. The heart/mediastinal ctivity ratio in the immediate 
images (15 min) showed a significant decrease only in patients 
with severe heart failure (groups 1 and 2). The myocardial 
washout was accelerated in all three heart failure groups. The 
level of myocardial washout was related to severity of heart failure 
and correlated well with New York Heart Association functional 
classification. 
Conclusions. In severe heart failure associated with cardiomy- 
opathy, norepinephrine uptake is reduced. In addition, myocar- 
dial adrenergic nerve activity is accelerated in proportion to 
severity of heart failure, independent of the underlying cause. 
(J Am Coil Cardiol 1995;26:1594-9) 
In patients with congestive heart failure, it has been demon- 
strated that plasma norepinephrine l vels are increased, gen- 
erally two to three times the levels observed in normal subjects 
(1,2), reflecting increased activation of the adrenergic nerve 
system (3). On the basis of findings of an increased aortocoro- 
nary sinus plasma catecholamine gradient (4,5) and an increase 
in the rate of norepinephrine spillover to plasma from the 
heart (6,7), intense myocardial drenergic nervous timulation 
has been suggested. Iodine-123 (I-123) metaiodobenzylgua- 
nidine (MIBG) is an analog of the adrenergic blocking agent 
guanethidine and shares many cellular transport properties 
with norepinephrine (8). It was developed as a clinical tool 
to visualize sympathetic nnervation and was recently used 
to study myocardial adrenergic nerve activity (9,10). In 
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patients with dilated cardiomyopathy, abnormal findings on 
myocardial MIBG images, such as a reduced myocardial/ 
mediastinal MIBG activity ratio, heterogeneous distribution 
of MIBG within the myocardium and increased MIBG 
washout from the heart have been demonstrated (11-13). 
These abnormal findings have been implicated as reflecting 
a loss of myocardial adrenergic nervous system integrity 
during heart failure, a combination of a reduced uptake (14) 
and increased release of norepinephrine from adrenergic 
nerve endings (4). 
However, heart failure also develops in the setting of work 
overload or mechanical abnormality, such as valvular heart 
disease, and abnormal findings on myocardial MIBG im- 
ages, such as high MIBG washout from heart, have been 
observed (15). However, whether these abnormal results 
vary according to the cause of the heart failure, and whether 
MIBG imaging is associated with severity of heart failure, is 
not known. To elucidate the change in myocardial adrener- 
gic nervous activity in patients with heart failure, we inves- 
tigated MIBG images from 96 patients with heart failure of 
various causes. 
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Table 1. Baseline Characteristics of Study Patients 
Group I Group 2 Group 3 
In : 40) (n 25) (n = 311 
Age (yr) 61 + 8 65 + 14 58 + 8 
Gender (M/F) 26/14 15/10 17/14 
LVEF (%) 21 _+ 5* 23 + 6* 56 + 7 
NYHA 
I 11 ~ 7 
II 1~ 10 15 
III/IV 11 t~ q 
Medical treatment 
Beta-blocker 13 (33) 5 (20) 5 (lOj 
Ca antagonist 10 (25) 7 (28) 7 (23) 
ACE inhibitor 21 (53) 8 (32) 15 (48) 
Digoxin 34 (85) 18 (72) 18 (58) 
*p < (}.0l groups 1 and 2 versus group 3. Data presented arc mean value + 
SD, number of patients or number (%) of patients. ACE inhibitor = angiotensin- 
converting enzyme inhibitor; Ca antagonist calcium channel antagonist; F - 
female; LVEF - left ventricular cjectinn fraction measured by routine radionu- 
ctide angiography; M = male: NYHA = New York Heart Association functional 
class. 
Methods 
Study patients. Participants in the study were 96 patients 
with heart failure. To clarify the influence of the underlying 
cause of heart failure on myocardial MIBG imaging, we 
classified the patients into three different groups. Groups 1 and 
2 included 65 patients with heart failure primarily ascribed to 
diminished myocardial contractility and whose left ventricular 
ejection fraction, measured by radionuclide angiography, was 
<40%: group 1 = 40 patients with dilated cardiomyopathy; 
group 2 - 25 patients with ischemic cardiomyopathy with 
global severe hypokinesia by radionuclide angiography. Group 
3 = 31 patients with heart failure primarily ascribed to 
mechanical abnormalities, such as valvular heart disease, 
whose left ventricular systolic function was preserved (>40%) 
(16 with mitral regurgitation. 9 with aortic regurgitation, 4 with 
mitral and aortic regurgitation, 2 with ruptured aneurysm of 
Valsalva). Patients with cardiomyopathy and significant valvu- 
lar dysfunction, and those with valvular heart disease whose 
left ventricular ejection fraction was <40%, were excluded to 
clarify the difference between groups 1 and 2 and group 3. 
Baseline characteristics of each group are shown in Table 1. 
Patients were taking a variety of medications at the time of the 
study, but none were taking tricyclic antidepressant or sym- 
pathomimetic agents or other drugs known to interfere with 
MIBG uptake. 
Control group. Nine normal subjects (four men, five 
women; mean [_+SD] age 58 = 3 years) who underwent 
clinical, hematologic and biochemical screening, chest radiog- 
raphy, rest and exercise lectrography and echography before 
admission to the study formed the control group. 
Protocol and imaging. Blood samples were drawn from 66 
inpatients for plasma human atrial natriuretic peptide (hANP) 
and norepinephrine d terminations after supine rest for a mini- 
mum of 1 h on the morning of the day of the MIBG imaging 
study. All medications, including digitalis preparations, diuretic 
drugs, beta-adrenergic blocking agents, angiotensin-converting 
enzyme inhibitors and calcium channel antagonists, were con- 
tinued; 2 mg of potassium iodide was given orally from 1 day 
before to 4 days after the study to block thyroid uptake of 1-123 
MIBG. Patients were placed in the supine position, and an 
intravenous catheter was placed in an antecubital vein. Iodine- 
123 MIBG was obtained commercially (Daiichi Radioisotope 
Laboratory, Tokyo, Japan); 111 MBq of 1-123 MIBG was 
injected and flushed with normal saline solution. Myocardial 
images were acquired using a standard-field gamma camera 
equipped with a low energy, parallel-hole collimator (SNC- 
500R, Shimazu, Kyoto, Japan). A 20% window centered at 
159 keV was used. Planar imaging was performed with con- 
verging collimators in the anterior view of the chest. The first 
acquisition began 15 rain after tracer injection (immediate image). 
Identical acquisition was obtained at 4 h after tracer injection 
(delayed image). Images were collected in a nuclear medicine 
computer for later analysis (Scintipac 2400, Shimazu). 
Gated radionuclide angiography was performed using a 
single-crystal scintillation camera (ZLC 3700, Siemens, Solna, 
Sweden) and the method of in vivo labeling of technetium-99m 
(Tc-99m) red blood cells with 740 MBq of Tc-99m. Processing 
of the data was accomplished with the Scintipac 2400. 
Image analysis. Left ventricular 1-123 MIBG activity was 
measured using a manually drawn region of interest around 
the left ventricular myocardium. A 20 x 20-pixel region of 
interest was placed over the upper mediastinal rea. Back- 
ground subtraction was performed using the upper mediastinal 
region of interest. To evaluate the myocardial ccumulation f 
MIBG, the heart/mediastinal (H/M) activity ratio was calcu- 
lated by the following formula from scintigrams obtained at 
15 rain (immediate image) and 4 h (delayed image) after 
isotope injection: 
H/M activity ratio = [H]/[M], 
where [H] = mean count/pixel in the left ventricle; and [M] = 
mean count/pixel in the upper mediastinum. Myocardial 
MIBG washout was defined as percent change in activity from 
the immediate and delayed images within the left ventricle as 
follows (10): 
{([H] - [M])~mm~d~t~ - ([H] - [M])de~.ye~}/([H] - [M])immediate X 100(%). 
Because systemic sympathetic activity is altered in patients 
with heart failure, accumulation a d washout of MIBG in the 
liver, which does not have dense adrenergic nnervation, were 
also measured and compared with those in the heart. A 20 x 
20-pixel region of interest was placed over the right lobe in the 
anterior view and analyzed in the same manner. 
Left ventricular diastolic function. In group 3, left ventric- 
ular systolic function was preserved, and we analyzed iastolic 
function. The indexes were 1) peak filling rate, determined by 
calculating the first derivative of the time-activity curve at the 
time of peak filling and expressed as end-diastolic ps; and 
2) time to peak filling rate, the time interval between end- 
systole to the time of peak left ventricular filling rate (16). 
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Neuroendocrine measurement. Blood samples for norepi- 
nephrine were withdrawn into prechilled tubes containing 
reduced glutathione and calcium chelator ethylenediaminetet- 
raacetic acid (EDTA) as preservative for norepinephrine 
analysis. The samples were centrifuged at 4°C at 2,500 rpm for 
12 rain. The norepinephrine analysis was performed by Bio- 
medical Laboratories (Tokyo, Japan) with high performance 
liquid chromatography with electrochemical detection. Blood 
samples for plasma hANP were withdrawn into evacuated 
EDTA tubes and centrifuged at 4°C at 2,500 rpm for 12 rain. 
Plasma hANP was also measured by Biomedical Laboratories 
with a simplified radioimmunoassay using commercially avail- 
able antibodies. 
Statistical analysis. Data are presented as mean value _+ 
SD. The chi-square test was used to compare categoric vari- 
ables. Comparison of more than two groups was performed by 
analysis of variance followed by the multiple comparison test 
(modified t test according to Bonferroni). Differences were 
considered statistically significant at p < 0.05. 
Results 
Plasma norepinephrine and hANP levels. Patients in New 
York Heart Association functional classes II and III/IV had 
significantly higher norepinephrine l vels, and to the same 
extent, than patients in functional class I (0.25 +_ 0.07, 0.49 _+ 
0.25, 0.56 _+ 0.31 ng/ml for functional classes I, II and III/1V, 
respectively, p < 0.01, class I vs. class II and class I vs. class 
III/IV). hANP levels were also higher in patients in functional 
class III/IV (33.8 _+ 21.1, 75.0 : 45.0, 155.9 _+ 102.7 pg/ml for 
functional classes I, II and III/IV, respectively, p < 0.01, classes 
I and II vs. class III/IV). 
Myocardial accumulation of MIBG. In the immediate im- 
ages, the heart/mediastinal activity ratio (Fig. 1) did not show 
any significant differences in Group 3 between any functional 
class or the control group. However, in group 1 and 2 patients 
in functional class III/IV, the heart/mediastinal activity ratio 
was decreased (p < 0.01) (Fig. 1, top). In the delayed images, 
the heart/mediastinal activity ratio decreased in group 1 and 2 
patients in functional classes II and Ill/IV and in group 3 
patients in functional class lII/IV (p < 0.01) (Fig. 1, bottom). 
Myocardial washout of MIBG. Myocardial washout of 
MIBG was increased in proportion to severity of congestive 
heart failure in all groups. There were no significant differ- 
ences between groups for any functional class (Fig. 2). Myo- 
cardial washout correlated positively with plasma norepineph- 
rine levels, but its correlation was weak (r = 0.38, p < 0.01) 
(Fig. 3, top). Myocardial washout also correlated positively 
with plasma hANP concentrations (r = 0.56, p < 0.01) (Fig. 3, 
bottom). 
Left ventricular diastolic function. The peak filling rate in 
group I and 2 patients in functional classes II and III/IV was 
significantly decreased (2.23 _+_ 1.05, 1.47 _+ I).46, 1.08 _+ 
0.41 cps for functional classes I, I1 and Ill/IV, respectively, p < 
0.01, class I vs. class II and class I vs. class Ill/IV), and the time 
to peak filling was prolonged in patients in functional class 
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Figure 1. Functional cardiac status (New York Heart Association 
[NYHA] classification) versus heart/mediastinal (H/M) activity ratio 
for each heart failure group. Top, Immediate images (after 15 rain). 
Bottom, Delayed images (after 4 h). Open bars = group 1; solid 
bars = group 2; dotted bars = group 3. Results are mean value 
(bars) _+ SD (vertical lines). **p < 0.01 versus control group (CONT). 
;p < IJ.01 versus functional class I. §p < 0.01 versus functional class lI. 
III/IV (20(I _+ 76, 202 _+ 58, 268 _+ 99 ms for functional classes 
I, II and III/IV, respectively, p < 0.01, classes I and II vs. class 
III/IV). The myocardial washout rate correlated inversely with 
the peak filling rate (r = -0.47, p < 0.01) (Fig. 4, top) and 
positively with the time to peak filling, although its correlation 
was weak (r = 0.31, p < 0.05) (Fig. 4, bottom). 
However, in group 3, the peak filling rate tended to be 
Figure 2. Functional cardiac status (New York Heart Association 
[NYHA] classification) versus myocardial washout (MWO) of MIBG 
in each heart failure group. **p < 0.01 versus control group (CONT). 
~p < 0.0l versus functional class I. §p < 0.0l versus functional class II. 
Other symbols as in Figure 1. 
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Figure 3. Relation between myocardial washout (MWO) and the 
concentration f plasma norepinephrine (pNE [top]) and plasma 
human atrial natriuretic peptide (hANP [bottom]). Myocardial wash- 
out and plasma norepinephrine levels were weakly correlated (r = 
0.38, p < 0.01); myocardial washout and hANP levels had a stronger 
correlation (r = 0.56, p < 0.01/. 
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Figure 4. Relation between myocardial washout (MWO) and peak 
filling rate (top) and time to peak filling (bottom). Myocardial washout 
and peak filling rate and time to peak filling were weakly correlated 
(r = -0.47, p < 0.01, myocardial washout vs. peak filling rate; r = 0.31, 
p < 0.05, myocardial washout vs. time to peak filling). 
decreased, and the time to peak filling tended to be prolonged, 
but not significantly (peak filling rate: 2.56 _+ 0.42, 2.33 + 0.63, 
2.16 _+ 0.67; time to peak filling: 174 _+ 31, 174 _+ 50, 241 _+ 
148 ms for functional classes I, II and III/IV, respectively). 
Myocardial washout did not show a significant correlation with 
these indexes (p = 0.72, myocardial washout vs. peak filling 
rate; p = 0.55, myocardial washout vs. time to peak filling). 
Accumulation and washout of MIBG in liver. The 
liver/mediastinal activity ratio was 2.91 +_ 0.52 in the immedi- 
ate image and 3.01 + 0.49 in the delayed image, and washout 
of MIBG in the liver was 32 +_ 15% in the control group. 
Accumulation and washout of MIBG in the liver did not show 
any significant differences in any functional class of any study 
group or the control group. 
Discuss ion  
The major finding of the present study is that patients with 
congestive heart failure have an accelerated myocardial wash- 
out of 1-123 MIBG that corresponds to the severity of heart 
failure; MIBG imaging results for the liver were similar in 
patients and control subjects. This evidence suggests that 
myocardial washout of MIBG increases, reflecting the intensi- 
fied myocardial adrenergic nervous activity in patients with 
heart failure. 
The MIBG is taken up by adrenergic tissues, and two types 
of uptake systems for MIBG have been identified: the neuro- 
nal uptake system, which predominates at low concentrations 
of MIBG, and the extraneuronal uptake system (17,18). The 
myocardial uptake of MIBG at low concentrations, used for 
clinical applications, represents mainly neuronal uptake 
(13,19,20). The MIBG is also taken up by liver, which does not 
have dense adrenergic nnervation (21). In our study, MIBG 
images of the liver were similar for all heart failure groups and 
the control group. Therefore, the abnormal myocardial MIBG 
imaging results observed in our study were assumed to be 
related specifically to adrenergic nervous activity in the heart. 
Myocardial uptake of MIBG. In the immediate images, the 
heart/mediastinal activity ratio was decreased only in Group 1 
and 2 patients in functional class Ill/IV. Controversy exists 
regarding the uptake ability of norepinephrine in a failing 
heart. Evidence has emerged to support both normal and 
reduced neuronal uptake of norepinephrine bycardiac adren- 
ergic nerves (6,7,22). The initial uptake ability for MIBG with 
heart failure patients i also controversial. Our data agree with 
earlier studies (13,15) showing that initial MIBG uptake is 
reduced in cardiomyopathy and normal in valve diseases but 
disagree with a study (12) showing that in patients with 
cardiomyopathy, initial MIBG imaging results are normal (12). 
However, in the latter study, patients with heart failure of 
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varying severity were compared with normal control subjects, 
and the extent of heart failure actually present in their study 
participants i unclear. Recently, a preliminary study (22) using 
human ventricular electrically stimulated cardiac preparations 
obtained from patients with cardiomyopathy demonstrated 
that uptake-1 activity is reduced in patients with severe heart 
failure. On the basis of these findings, we consider that our 
data indicated that the initial uptake of MIBG varied accord- 
ing to severity of heart failure and that it was reduced in 
patients with severe heart failure caused by cardiomyopathy. 
The reason that the heart/mediastinal activity ratio in the 
immediate images from group 3 was not reduced isnot certain. 
It has been demonstrated (23,24) that when myocardial func- 
tion fails, an alteration of neuronal function follows. In our 
study, patients with valve disease and an ejection fraction 
<40% were excluded. Thus, myocardial function in group 3 
was presumably preserved. The lack of myocardial dysfunction 
may be the reason for the normal heart/mediastinal activity 
ratio. Consequently, the low heart/mediastinal activity ratio 
observed in group 1 and 2 patients in functional class III/IV 
may reflect the possibility that the uptake ability of norepi- 
nephrine is reduced in severe congestive heart failure caused 
by cardiomyopathy because of myocardial injury. 
In the delayed images, the heart/mediastinal activity ratio was 
reduced in all three heart failure groups. This finding agrees with 
other studies (11,25) demonstrating that the heart/mediastinal 
ratio obtained 2 or 4 h after isotope injection is reduced in 
patients with heart failure due to cardiomyopathy. However, the 
heart/mediastinal activity ratio in the delayed images has limited 
use as an index of uptake ability or turnover of MIBG because it
is affected by both the initial uptake and washout of MIBG. Our 
data demonstrated that the heart/mediastinal ratio in the imme- 
diate images differed between groups and that washout of MIBG 
also differed. In cases associated with altered MIBG initial uptake 
and washout, he heart/mediastinal activity ratio in the delayed 
images may not precisely represent uptake ability or turnover. 
Therefore, on the basis of findings obtained from the immediate 
images, we consider that the uptake of norepinephrine was 
reduced only in patients with severe heart failure caused by 
cardiomyopathy. 
Myocardial washout of MIBG. Myocardial washout of 
MIBG was accelerated in proportion to severity of heart 
failure in all groups. There were no significant differences 
between the groups for any functional class. Acceleration of 
washout was not observed in the liver and thus was not a 
general change in patients with heart failure. These results are 
supported by earlier studies (4-7) demonstrating that neuronal 
norepinephrine turnover in the heart is increased in patients 
with heart failure. From our results, we consider that regard- 
less of the cause, intensification of the cardiac adrenergic 
nervous system was elicited according to severity of heart 
failure, which in turn accelerated MIBG release in proportion 
to adrenergic nervous activity. 
We believe that in contrast to the heart/mediastinal activity 
ratio, washout ismore useful as an index of adrenergic nervous 
activity because it is independent of the number of neurons 
available, whereas the heart/mediastinal activity ratio is not. 
Therefore, although the heart/mediastinal activity ratio and 
washout represent different functions of adrenergic presynap- 
tic activity, washout may be a more accurate marker of severity 
of heart failure. 
Left ventrieular diastolic function. Left ventricular dia- 
stolic function was impaired in patients in groups 1 and 2, and 
washout correlated weakly with diastolic function. Our findings 
corroborated previous reports (26-28) that in patients with 
dilated cardiomyopathy and ischemic heart disease, left ven- 
tricular diastolic function was depressed, which contributed to
congestive heart failure. 
Although left ventricular diastolic function tended to be 
depressed inpatients in group 3, but not statistically significant, 
there was no correlation between washout and diastolic func- 
tion. These results may have occurred because left ventricular 
diastolic function is not a primary factor in determining 
severity of heart failure. These results also implied that 
whether there is myocardial dysfunction i patients with heart 
failure, an intense myocardial adrenergic activity is elicited. 
Plasma norepinephrine and hANP. Concentrations of 
hANP correlated positively with myocardial washout. Plasma 
norepinephrine l vels also showed a significant but weak 
correlation with myocardial washout. The hANP has an inhib- 
itory effect on sympathetic nerve activity (29), but an increase 
in myocardial washout preceded the increase in concentration 
of hANP. Contrary to its sympathoinhibitory effect, myocardial 
washout showed a positive correlation with hANP concentra- 
tions. Accordingly, direct inhibition of MIBG kinetics by 
hANP was presumably small. In congestive heart failure, 
excessive l vels of hANP have been reported (30), as well as a 
positive correlation between plasma hANP concentration a d 
severity of heart failure (31,32). We therefore consider that he 
myocardial washout and hANP may represent severity of heart 
failure independently, myocardial washout by reflecting inten- 
sified adrenergic nervous activity and hANP by reflecting 
elevated atrial pressure. 
It is possible that an increase in norepinephrine levels could 
compete with MIBG. However, the correlation with plasma 
norepinephrine and myocardial washout was weak, and be- 
tween functional classes II and III/IV, although the norepi- 
nephrine concentration was almost the same, a significant 
difference in myocardial washout was observed. Our data 
indicate that interference between plasma norepinephrine 
levels and MIBG kinetics is weak, if present at all. In patients 
with heart failure, elevation of endogenous catecholamine 
levels has been demonstrated, but its correlation with severity 
of heart failure is controversial. Because plasma norepineph- 
fine levels reflect overall systemic adrenergic activity, the 
circulating catecholamine concentration is not an accurate 
index of changes in cardiac adrenergic activity (2,33). With 
MIBG imaging, it is possible to assess cardiac adrenergic 
activity specifically by setting the region of interest on the 
heart. Therefore, we consider MIBG imaging to be a more 
accurate way of evaluating myocardial adrenergic activity. 
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Conclus ions.  lod ine-123 MIBG imaging reflects myocar-  
dial adrenerg ic  activity in pat ients  with heart  fai lure. A l though 
the initial uptake abil ity of M IBG was different among var ious 
under ly ing diseases, storage and release of M IBG,  calculated 
as the washout  rate of M IBG f rom the heart ,  represents  
intensi f ied activity of adrenerg ic  activity independent  of the 
under ly ing cause. Analysis  of M IBG imaging, especial ly its 
washout  rate f rom the heart ,  is a useful, noninvas ive tool for 
evaluat ing severity of hear t  failure. 
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